In 1996, Allison and his colleagues demonstrated through animal models that inhibitory antibodies that block CTLA-4 can boost the immune response against tumors, marking the first successful application of CTLA-4 in cancer treatment [87]. The gene discussed is CTLA4; the disease is cancer.